# Transconjunctival suprachoroidal buckling for rhegmatogenous retinal detachment

## TL;DR

A new office-friendly technique for treating retinal detachment shows high success rates and fewer complications than traditional methods.

## Contribution

The study introduces and evaluates a novel transconjunctival suprachoroidal buckle technique for primary retinal detachment.

## Key findings

- The TSCB technique achieved retinal attachment in all 31 patients with primary RRD.
- Only 10% of patients required a second surgery, and 6% developed dot hemorrhage from choroidal puncture.
- The procedure can be performed in the office for uncomplicated cases, avoiding conventional scleral buckling complications.

## Abstract

To assess the effectiveness of the transconjunctival suprachoroidal buckle (TSCB) technique in treating primary rhegmatogenous retinal detachment (RRD).

A prospective interventional study including patients with primary RRD undergoing the TSCB technique. The technique consisted of a transconjunctival approach using an olive tip handled cannula with an Atkinson 25-gauge needle tip that injects a high-purity gel in the suprachoroidal space (SCS) and creates a buckle effect that lasts for 12–18 months. Indirect laser retinopexy is done in the operating room or in the early post-operative office visit on the slit lamp. The TSCB technique could be done in the office in selected cases of uncomplicated RRD.

The study included 31 eyes of 31 patients. Seventeen eyes were phakic (55%). The RRD involved one quadrant in 81% of eyes. Sixteen eyes (52%) had more than one break. The TSCB procedure was performed in the operating room in 21 patients (68%). The mean duration of follow-up was 5 months. Postoperatively, we achieved retinal attachment in all patients. Three patients (10%) needed a second surgery. Two patients (6%) developed dot hemorrhage due to choroidal puncture.

The TSCB is safe, and avoids the complications of conventional scleral buckling.

The online version contains supplementary material available at 10.1186/s40942-025-00774-2.